IRWD
Income statement / Annual
Last year (2024), Ironwood Pharmaceuticals, Inc.'s total revenue was $351.41 M,
a decrease of 20.63% from the previous year.
In 2024, Ironwood Pharmaceuticals, Inc.'s net income was $130.75 M.
See Ironwood Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$351.41 M |
$442.74 M |
$410.60 M |
$413.75 M |
$389.52 M |
$428.41 M |
$346.64 M |
$298.28 M |
$273.96 M |
$149.56 M |
| Cost of Revenue |
$0.00
|
$104.79 M
|
$1.42 M
|
$1.52 M
|
$3.14 M
|
$23.88 M
|
$32.75 M
|
$19.41 M
|
$1.87 M
|
$12,000.00
|
| Gross Profit |
$351.41 M
|
$337.95 M
|
$409.18 M
|
$412.23 M
|
$386.39 M
|
$404.54 M
|
$313.89 M
|
$278.87 M
|
$272.09 M
|
$149.54 M
|
| Gross Profit Ratio |
1
|
0.76
|
1
|
1
|
0.99
|
0.94
|
0.91
|
0.93
|
0.99
|
1
|
| Research and Development Expenses |
$109.96 M
|
$116.09 M
|
$44.27 M
|
$70.41 M
|
$88.06 M
|
$115.04 M
|
$166.50 M
|
$148.23 M
|
$139.49 M
|
$108.75 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$241.29 M
|
$233.12 M
|
$173.28 M
|
$125.25 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$144.01 M
|
$158.31 M
|
$115.99 M
|
$111.13 M
|
$140.00 M
|
$172.45 M
|
$241.29 M
|
$233.12 M
|
$173.28 M
|
$125.25 M
|
| Other Expenses |
$0.00
|
$1.01 B
|
$0.00
|
$0.00
|
$24,000.00
|
$514,000.00
|
$8.11 M
|
$6.21 M
|
$981,000.00
|
$17.64 M
|
| Operating Expenses |
$253.97 M
|
$1.28 B
|
$160.26 M
|
$181.54 M
|
$228.07 M
|
$287.49 M
|
$415.91 M
|
$387.57 M
|
$313.75 M
|
$233.99 M
|
| Cost And Expenses |
$256.56 M
|
$1.39 B
|
$160.26 M
|
$181.54 M
|
$231.20 M
|
$311.37 M
|
$448.66 M
|
$406.97 M
|
$315.62 M
|
$234.01 M
|
| Interest Income |
$4.47 M
|
$18.97 M
|
$9.50 M
|
$726,000.00
|
$1.50 M
|
$2.86 M
|
$2.99 M
|
$2.11 M
|
$1.17 M
|
$443,000.00
|
| Interest Expense |
-$33.04 M
|
$21.63 M
|
$7.60 M
|
$31.15 M
|
$29.48 M
|
$36.60 M
|
$34.73 M
|
$34.26 M
|
$37.98 M
|
$30.65 M
|
| Depreciation & Amortization |
$0.00
|
$1.58 M
|
$1.42 M
|
$1.52 M
|
$3.56 M
|
$5.58 M
|
$11.97 M
|
$14.62 M
|
$11.26 M
|
$11.63 M
|
| EBITDA |
$94.85 M |
-$924.86 M |
$261.44 M |
$233.33 M |
$141.90 M |
$101.13 M |
-$144.45 M |
-$33.12 M |
-$31.30 M |
-$99.94 M |
| EBITDA Ratio |
0.27
|
-2.09
|
0.63
|
0.56
|
0.41
|
0.28
|
-0.27
|
-0.34
|
-0.15
|
-0.56
|
| Operating Income Ratio |
0.27
|
-2.14
|
0.61
|
0.56
|
0.37
|
0.28
|
-0.69
|
-0.26
|
-0.19
|
-0.68
|
| Total Other Income/Expenses Net |
-$28.57 M
|
-$2.64 M
|
$2.09 M
|
-$31.60 M
|
-$34.08 M
|
-$61.18 M
|
-$43.48 M
|
-$71.16 M
|
-$29.84 M
|
-$40.58 M
|
| Income Before Tax |
$66.28 M
|
-$948.07 M
|
$252.42 M
|
$200.66 M
|
$108.86 M
|
$58.94 M
|
-$282.37 M
|
-$116.94 M
|
-$81.71 M
|
-$142.67 M
|
| Income Before Tax Ratio |
0.19
|
-2.14
|
0.61
|
0.48
|
0.28
|
0.14
|
-0.81
|
-0.39
|
-0.3
|
-0.95
|
| Income Tax Expense |
-$64.47 M
|
$83.49 M
|
$77.36 M
|
-$327.79 M
|
$2.69 M
|
$74.26 M
|
-$5.75 M
|
$34.26 M
|
$37.98 M
|
$19.02 M
|
| Net Income |
$130.75 M
|
-$1.00 B
|
$175.07 M
|
$528.45 M
|
$106.18 M
|
-$15.31 M
|
-$282.37 M
|
-$116.94 M
|
-$81.71 M
|
-$142.67 M
|
| Net Income Ratio |
0.37
|
-2.26
|
0.43
|
1.28
|
0.27
|
-0.04
|
-0.81
|
-0.39
|
-0.3
|
-0.95
|
| EPS |
0.82 |
-6.45 |
1.13 |
3.26 |
0.67 |
-0.0982 |
-1.85 |
-0.79 |
-0.56 |
-1 |
| EPS Diluted |
0.82 |
-6.45 |
0.94 |
3.21 |
0.66 |
-0.0982 |
-1.85 |
-0.78 |
-0.56 |
-1 |
| Weighted Average Shares Out |
$159.71 M
|
$155.44 M
|
$154.37 M
|
$162.25 M
|
$159.43 M
|
$156.02 M
|
$152.63 M
|
$148.42 M
|
$144.93 M
|
$142.16 M
|
| Weighted Average Shares Out Diluted |
$160.23 M
|
$155.44 M
|
$186.31 M
|
$164.42 M
|
$160.66 M
|
$156.02 M
|
$152.63 M
|
$148.99 M
|
$145.91 M
|
$142.16 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
